Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Camrelizumab|DRUG: Apatinib|DRUG: Nab-paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: West China Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.